Eisai Subscribes to Incyte s LifeSeq Gold and ZooSeq

Apr 09, 2001

NEW YORK, April 9 - Eisai, a Japanese health care and pharmaceutical company, has signed a multi-year subscription to Incyte Genomics' LifeSeq Gold human sequence and ZooSeq animal model databases, the company said Monday.

Researchers at Eisai, which is based in Tokyo, will have 24-hour online access to the databases and to information technology support, Incyte said in a statement.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Breaking News

The Scan

An Expensive Deal

While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.

Figuring Out Who It'll Work For

Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.

This Week in Nature

In Nature this week: paternal age associated with de novo mutations in children, and more.

Ye Old P-Value

Nature News writes that researchers are still wrangling over the role of the p-value.

Main menu